Morgan Stanley Maintains a Hold on Pfizer (PFE)

Pfizer Inc. (NYSE:PFE) is one of the top low volatility healthcare stocks to buy now. On July 22, Morgan Stanley analyst Terence Flynn maintained a Hold rating on Pfizer Inc. (NYSE:PFE) and set a price target of $32.00.

One of the primary factors behind this cautious rating is the impending patent expiration for Pfizer’s Tafamidis, marketed as Vyndamax and Vyndaqel, which may result in a considerable revenue decline.

The analyst reasoned that the patent cliff, which is expected later in the decade, may lead to lost revenue of around $20 billion. The market recognizes this factor, as it is reflected in Pfizer Inc.’s (NYSE:PFE) lower P/E ratio compared to historical industry averages and the S&P 500.

Flynn further stated that while Tafamidis is a successful product with expected sales of $6.4 billion in 2025, the patent expirations in the US and EU pose a challenge to Pfizer Inc. (NYSE:PFE).

Pfizer Inc. (NYSE:PFE) is a global biopharmaceutical company that manufactures, develops, markets, and sells biopharmaceutical products worldwide. It advances wellness, prevention, treatment, and cures in developing and emerging markets.

While we acknowledge the potential of PFE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.